Anti-anginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: a multicenter study. - Wikidata - wikimedia - TriplyDB

Anti-anginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: a multicenter study.

Anti-anginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: a multicenter study.

http://www.wikidata.org/entity/Q44200627

about

The Function of Rho-Associated Kinases ROCK1 and ROCK2 in the Pathogenesis of Cardiovascular Disease The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis Small G proteins in the cardiovascular system: physiological and pathological aspects Integrin-linked kinase is required for radial sorting of axons and Schwann cell remyelination in the peripheral nervous system Little ROCK is a ROCK1 pseudogene expressed in human smooth muscle cells Fasudil improves survival and promotes skeletal muscle development in a mouse model of spinal muscular atrophy New approaches to the treatment of pulmonary hypertension: from bench to bedside.The role of rho kinase in sex-dependent vascular dysfunction in type 1 diabetes.Rho/Rho-associated coiled-coil forming kinase pathway as therapeutic targets for statins in atherosclerosis.RhoA/Rho-kinase and vascular diseases: what is the link?Rho-associated coiled-coil-forming kinases (ROCKs): potential targets for the treatment of atherosclerosis and vascular disease.HIV-1 Tat activates a RhoA signaling pathway to reduce NMDA-evoked calcium responses in hippocampal neurons via an actin-dependent mechanism Rho-kinase activation in leukocytes plays a pivotal role in myocardial ischemia/reperfusion injury.Multimodal effects of small molecule ROCK and LIMK inhibitors on mitosis, and their implication as anti-leukemia agents.Critical role of exogenous nitric oxide in ROCK activity in vascular smooth muscle cells.Rho kinase as a therapeutic target in cardiovascular disease.Direct inhibition of myosin II effectively blocks glioma invasion in the presence of multiple motogens.Rho kinase, a promising drug target for neurological disorders.ROCKs as therapeutic targets in cardiovascular diseases Cardiovascular effects of a novel potent and highly selective azaindole-based inhibitor of Rho-kinase.Rho kinase as potential therapeutic target for cardiovascular diseases: opportunities and challenges.Anti-inflammatory effects of statins: clinical evidence and basic mechanisms.Physiological role of ROCKs in the cardiovascular system Applications for ROCK kinase inhibition The therapeutic effects of Rho-ROCK inhibitors on CNS disorders.Rho kinase (ROCK) inhibitors.Enhanced rho-associated protein kinase activation in patients with systemic lupus erythematosus.Inhibition of ROCK activity allows InlF-mediated invasion and increased virulence of Listeria monocytogenes.Exogenous nitric oxide inhibits Rho-associated kinase activity in patients with angina pectoris: a randomized controlled trial.Roles of rho-associated kinase and oxidative stress in the pathogenesis of aortic stiffness Rho kinase inhibition improves endothelial function in human subjects with coronary artery disease.Measurement of Rho-associated kinase (ROCK) activity in humans: validity of leukocyte p-MBS/t-MBS in comparison with vascular response to fasudil Signaling through Rho GTPase pathway as viable drug target.Fasudil, a rho kinase inhibitor, limits motor neuron loss in experimental models of amyotrophic lateral sclerosis Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation.Rho kinases in cardiovascular physiology and pathophysiology: the effect of fasudil.RhoA/Rho-kinase signaling: a therapeutic target in pulmonary hypertension.Involvement of RhoA/ROCK in myocardial fibrosis in a rat model of type 2 diabetes.Emerging medical treatment for angina pectoris.Rho-kinase inhibition: a novel therapeutic target for the treatment of cardiovascular diseases.

P2860

Q26774795-6DAB3FC5-48AF-4482-A4CC-58F04E938464 Q27005980-39B44D40-6650-4F0A-B958-0D99D865641C Q27010607-00B81362-1906-4402-8624-3CB5A17471EC Q28587844-E73228FA-5981-432F-B9A9-F619FDC65C46 Q28752240-3B7E94A3-7E98-4277-9A18-6EBF5C16A454 Q30511954-1D5CD911-7625-417B-BE3A-0C10AD3ED911 Q33690368-6256A7B0-A31C-433C-A37C-D7723ADFEC94 Q33756580-79CA45C7-1703-4D65-AA69-4F6E4A55F3AB Q34362144-E71EF240-50A0-4C4A-865B-7F1E60A1FCBC Q34378293-13435691-4E7F-40CA-A6B5-661BDFF32B33 Q34823543-275E8076-BAB0-46C2-A4D2-E6F5B5957464 Q35007551-FFBBD362-6899-414A-BE19-97661AE02A1B Q35123172-25A6A89D-1F39-422F-8C7B-612D2FD314E0 Q35123961-15966FE5-6874-474E-9608-D769D8322D21 Q35299517-63C42344-DC0F-4B2E-8334-02F9829893F7 Q35352722-3CADF143-98A9-4132-9897-D4CDABC1289E Q35756665-D8F27528-4019-4403-9196-7573AB24CA42 Q36111908-6D7FBABC-44A0-41EF-AF58-14F95A6DF204 Q36124892-58DABB39-75DC-4CC3-88DA-0EFAE839BE30 Q36171342-0138B564-1807-42B8-BF54-165366C42B7D Q36219699-80AD3FB4-DD82-49D6-8DF0-2C1962096AB1 Q36337932-D862E981-43AA-4AF0-8719-9935A011EA03 Q36392528-BB401A63-D7CF-42F0-878E-24D3B635829D Q36649417-B36A5317-D160-42FF-9B3A-377B233DF815 Q36818193-66B6BF8B-E3AC-4C08-ACA1-64AB1CA83446 Q36897945-04B7170B-1885-4EC0-89A4-BD7E315D3A05 Q36901827-F988D0A2-A48C-44DB-955A-6CB661F82AE1 Q36955621-B2DE846B-DB93-47BC-A7B5-1392EEE970AC Q36957526-1312C7A2-3610-47C1-8F16-1949EBE82CDE Q37041726-D0F5A736-68B3-42A3-A4F9-C83D5721F29F Q37151565-8C8FAF5A-F8DC-414D-8354-E235A2F87F21 Q37252134-038B19F2-2B9D-4A73-B3BE-E05855010771 Q37312315-3B3B2EF1-7AEA-4F4F-BD82-01255B5CC2C4 Q37327385-59A1EF21-1E36-43DA-A6F1-9090E7D3E48A Q37351215-49FE6577-ACED-49FF-BD37-98CA03779AAE Q37450106-C6B91E43-04C0-4B02-85E6-EAD255ABEBC7 Q37586828-5C6CBFF1-390D-4140-814C-979A1DBCAFF9 Q37728377-A8C69F02-CD9C-40E5-8F81-7713E614E1FA Q37729183-22E5FF3E-1C2C-4D58-995F-90F6A9CF14E2 Q37769931-0C2A21D1-4E20-435C-BBB3-F10C9307D70D

P2860

Anti-anginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: a multicenter study.

http://www.wikidata.org/entity/Q44200627

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh-hant

name

Anti-anginal effect of fasudil ...... t angina: a multicenter study.

@en

Anti-anginal effect of fasudil ...... t angina: a multicenter study.

@nl

type

label

Anti-anginal effect of fasudil ...... t angina: a multicenter study.

@en

Anti-anginal effect of fasudil ...... t angina: a multicenter study.

@nl

prefLabel

Anti-anginal effect of fasudil ...... t angina: a multicenter study.

@en

Anti-anginal effect of fasudil ...... t angina: a multicenter study.

@nl

P1433

Q44200627-3400D75F-E861-4B8B-BECC-C20CCA9A7A93

P1476

Q44200627-8E1F56D2-E4C9-467F-B94C-826E3DC80E87

P2093

Q44200627-0B8038D2-8D7C-4D78-BEC4-674CDDB4C69F

Q44200627-11B18131-9C4C-42EF-ACD6-3B4C5435593C

Q44200627-3C591CC8-8B93-4C68-AC76-4E9626AA45D6

Q44200627-578C6182-541F-4C07-97C4-C9EA593EDD97

Q44200627-59D5FEEB-01F4-4ADB-9375-0C738D969D93

Q44200627-6BAB4007-0ADB-4E86-AB62-8001A0B3D621

Q44200627-743DD53D-E5C9-483F-889F-B6C752278155

Q44200627-9118775F-5480-4F23-A867-39C43C6E6999

Q44200627-C2CACA5D-CCF4-4162-9088-66375BB75848

Q44200627-CDF0672B-BED5-428F-A403-900647DC5704

P304

Q44200627-ABA78038-AFB0-47E6-BC01-268C33EB8045

P31

Q44200627-83113DEC-6FBC-4DBC-9FA3-FFCD7EA5E42C

P356

Q44200627-05CBCA3A-7457-455A-AB8A-49AF62324170

P407

Q44200627-FEC024B8-0F6B-4D60-BAC2-57F3D3A94E64

P433

Q44200627-C4A5694A-91D2-48B1-B2D2-BC74CFF3BF3A

P478

Q44200627-7D5D8DE9-4FBF-4E59-B54F-5A12F83CBF2E

P577

Q44200627-91F51C35-287F-43E2-849B-A809DDD95EE0

P698

Q44200627-EBAF3AD2-27A4-4829-9B9F-406B7DD64D17

P356

00005344-200211000-00013

P1433

Journal of Cardiovascular Pharmacology

P1476

Anti-anginal effect of fasudil ...... t angina: a multicenter study.

@en

P2093

Hiroaki Shimokawa

http://www.w3.org/2001/XMLSchema#string

Hirofumi Osada

http://www.w3.org/2001/XMLSchema#string

Hiroshi Kishida

http://www.w3.org/2001/XMLSchema#string

Hiroyuki Iinuma

http://www.w3.org/2001/XMLSchema#string

Katsuhiko Hiramori

http://www.w3.org/2001/XMLSchema#string

Kazunobu Yamauchi

http://www.w3.org/2001/XMLSchema#string

Kazuzo Kato

http://www.w3.org/2001/XMLSchema#string

Mitsuyoshi Nakashima

http://www.w3.org/2001/XMLSchema#string

Saichi Hosoda

http://www.w3.org/2001/XMLSchema#string

Takashi Katagiri

http://www.w3.org/2001/XMLSchema#string

P304

751-761

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/00005344-200211000-00013

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

40

http://www.w3.org/2001/XMLSchema#string

P577

2002-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12409984

http://www.w3.org/2001/XMLSchema#string